In contrast, in more aggressive B‐cell malignancies, including diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), responses to single agent BTK inhibitors (BTKi) occur only in subsets of patients and are mostly of brief duration. The gene discussed is BTK; the disease is mantle cell lymphoma.